PPARD and obesity disorder: Recent reports have shown that PPARδ agonists attenuated obesity-related diseases such as insulin resistance, diabetes and cardiovascular diseases, and regulated inflammatory cell function, which potentiated a systemic inflammatory response [18], [19], [20], [21], [22], [32], [33], [34].